ID: ALA2152204

Max Phase: Preclinical

Molecular Formula: C24H29N3O5S

Molecular Weight: 471.58

Molecule Type: Small molecule

Representations

Canonical SMILES:  C=CC(=O)NC1CCN(S(=O)(=O)c2ccc(C(=O)NCCc3ccc(OC)cc3)cc2)CC1

Standard InChI:  InChI=1S/C24H29N3O5S/c1-3-23(28)26-20-13-16-27(17-14-20)33(30,31)22-10-6-19(7-11-22)24(29)25-15-12-18-4-8-21(32-2)9-5-18/h3-11,20H,1,12-17H2,2H3,(H,25,29)(H,26,28)

Standard InChI Key:  NAKBZGQGRIHKEQ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 471.58

Molecular Weight (Monoisotopic): 471.1828

AlogP: 2.12

#Rotatable Bonds: 9

Polar Surface Area: 104.81

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.92

CX Basic pKa:

CX LogP: 1.74

CX LogD: 1.74

Aromatic Rings: 2

Heavy Atoms: 33

QED Weighted: 0.55

Np Likeness Score: -1.23

References

1. Prime ME, Brookfield FA, Courtney SM, Gaines S, Marston RW, Ichihara O, Li M, Vaidya D, Williams H, Pedret-Dunn A, Reed L, Schaertl S, Toledo-Sherman L, Beconi M, Macdonald D, Muñoz-Sanjuan I, Dominguez C, Wityak J..  (2012)  Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease.,  3  (9): [PMID:24900540] [10.1021/ml3001352]

2. Ahamad S, Bhat SA..  (2022)  The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease.,  65  (24.0): [PMID:36490325] [10.1021/acs.jmedchem.2c00799]

Source

Source(1):

• Scientific Literature